Novartis announced the acquisition of biotechnology company Excellergy. The subject of the acquisition are new generation anti-IgE therapies developed by Excellergy. Novartis will pay $2 billion up front for Excellergy. The acquisition will strengthen Novartis' immunology portfolio. The goal is the development of innovative therapies for patients with IgE-mediated diseases. The transaction is subject to customary closing conditions.